Literature DB >> 19617576

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.

Mary Cushman1, Ellen S O'Meara, Aaron R Folsom, Susan R Heckbert.   

Abstract

Higher levels of procoagulant factors and factor XII deficiency may be risk factors for first venous thromboembolism (VTE). We studied associations of coagulation factors IX through XIII with risk of future VTE in 2 general population samples. Using a nested case-control study combining the 21 860 participants of the Atherosclerosis Risk in Communities study and the Cardiovascular Health Study, we determined antigenic levels of these coagulation factors in primarily pre-event blood samples from 462 participants who subsequently developed VTE and 1047 participants who remained free of VTE. Only elevated levels of factors IX and XI were associated with increased risk of VTE after adjustment for age, sex, race, and study. For factor IX, the odds ratio (OR) was 1.4 (95% confidence interval [CI], 1.0-2.0) comparing the top to bottom quintile. The OR for factor XI was higher: 2.0 (95% CI, 1.4-2.9). With further adjustment for body mass index and diabetes, only elevated factor XI remained associated with VTE risk: OR 1.8 (95% CI, 1.3-2.7). Associations were similar by study and whether the thrombosis was idiopathic or secondary. Factor XII deficiency was not related to VTE risk. Among these procoagulant factors, only elevated factor XI was a risk factor for VTE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617576      PMCID: PMC2756198          DOI: 10.1182/blood-2009-05-219915

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis.

Authors:  G D Lowe; F Haverkate; S G Thompson; R M Turner; R M Bertina; A G Turpie; P M Mannucci
Journal:  Thromb Haemost       Date:  1999-06       Impact factor: 5.249

2.  The 46C-->T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis.

Authors:  R M Bertina; S R Poort; H L Vos; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2005-03       Impact factor: 5.824

3.  Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.

Authors:  Peter A von dem Borne; Linda M P Cox; Bonno N Bouma
Journal:  Blood Coagul Fibrinolysis       Date:  2006-06       Impact factor: 1.276

4.  Factor XII gene (F12) -4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis.

Authors:  Taisuke Kanaji; Kumiko Watanabe; Sachiko Hattori; Michiyo Urata; Hiroko Iida; Sachiko Kinoshita; Yuzo Kayamori; Dongchon Kang; Naotaka Hamasaki
Journal:  Thromb Haemost       Date:  2006-12       Impact factor: 5.249

5.  Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy.

Authors:  E Cochery-Nouvellon; E Mercier; G Lissalde-Lavigne; J-P Daurès; I Quéré; M Dauzat; P Marès; J-C Gris
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

Review 6.  Epidemiology and risk factors for venous thrombosis.

Authors:  Mary Cushman
Journal:  Semin Hematol       Date:  2007-04       Impact factor: 3.851

7.  Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis.

Authors:  Philip S Wells; Josdalyne L Anderson; Dimitrios K Scarvelis; Steve P Doucette; France Gagnon
Journal:  Am J Epidemiol       Date:  2006-06-01       Impact factor: 4.897

8.  Association of genetic variations with nonfatal venous thrombosis in postmenopausal women.

Authors:  Nicholas L Smith; Lucia A Hindorff; Susan R Heckbert; Rozenn N Lemaitre; Kristin D Marciante; Kenneth Rice; Thomas Lumley; Joshua C Bis; Kerri L Wiggins; Frits R Rosendaal; Bruce M Psaty
Journal:  JAMA       Date:  2007-02-07       Impact factor: 56.272

Review 9.  Thrombophilia: common questions on laboratory assessment and management.

Authors:  John A Heit
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

10.  ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  T Ohira; M Cushman; M Y Tsai; Y Zhang; S R Heckbert; N A Zakai; W D Rosamond; A R Folsom
Journal:  J Thromb Haemost       Date:  2007-04-09       Impact factor: 5.824

View more
  41 in total

1.  Coagulation procofactor activation by factor XIa.

Authors:  M F Whelihan; T Orfeo; M T Gissel; K G Mann
Journal:  J Thromb Haemost       Date:  2010-05-04       Impact factor: 5.824

Review 2.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

3.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 4.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

5.  Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Mary Cushman; Ellen S O'Meara; Susan R Heckbert; Neil A Zakai; Wayne Rosamond; Aaron R Folsom
Journal:  Thromb Res       Date:  2016-06-15       Impact factor: 3.944

6.  Relation of coagulation factor XI with incident coronary heart disease and stroke: the Cardiovascular Health Study.

Authors:  Duke Appiah; Oluwaseun E Fashanu; Susa R Heckbert; Mary Cushman; Bruce M Psaty; Aaron R Folsom
Journal:  Blood Coagul Fibrinolysis       Date:  2017-07       Impact factor: 1.276

7.  Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Aaron R Folsom; Kristen M George; Duke Appiah
Journal:  Atherosclerosis       Date:  2015-09-10       Impact factor: 5.162

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

9.  Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Authors:  Harry R Büller; Claudette Bethune; Sanjay Bhanot; David Gailani; Brett P Monia; Gary E Raskob; Annelise Segers; Peter Verhamme; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2014-12-07       Impact factor: 91.245

10.  Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.

Authors:  N C Olson; S Butenas; L A Lange; E M Lange; M Cushman; N S Jenny; J Walston; J C Souto; J M Soria; G Chauhan; S Debette; W T Longstreth; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2015-09-14       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.